Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar;14(3):521-538.
doi: 10.1002/term.3004. Epub 2019 Dec 22.

Limitations of recellularized biological scaffolds for human transplantation

Affiliations
Review

Limitations of recellularized biological scaffolds for human transplantation

Claudia Bilodeau et al. J Tissue Eng Regen Med. 2020 Mar.

Abstract

A shortage of donor organs for transplantation and the dependence of the recipients on immunosuppressive therapy have motivated researchers to consider alternative regenerative approaches. The answer may reside in acellular scaffolds generated from cadaveric human and animal tissues. Acellular scaffolds are expected to preserve the architectural and mechanical properties of the original organ, permitting cell attachment, growth, and differentiation. Although theoretically, the use of acellular scaffolds for transplantation should pose no threat to the recipient's immune system, experimental data have revealed significant immune responses to allogeneic and xenogeneic transplanted scaffolds. Herein, we review the various factors of the scaffold that could trigger an inflammatory and/or immune response, thereby compromising its use for human transplant therapy. In addition, we provide an overview of the major cell types that have been considered for recellularization of the scaffold and their potential contribution to triggering an immune response.

Keywords: extracellular matrices; immune response; recellularization; scaffolds; stem cells; transplantation.

PubMed Disclaimer

References

REFERENCES

    1. Abolbashari, M., Agcaoili, S. M., Lee, M.-K., Ko, I., Aboushwareb, T., Jackson, J. D., … Atala, A. (2016). Repopulation of porcine kidney scaffold using porcine primary renal cells. Acta Biomaterialia, 29, 52-61.
    1. Andrews, P. W., Ben-David, U., Benvenisty, N., Coffey, P., Eggan, K., Knowles, B. B., … Stacey, G. N. (2017). Assessing the safety of human pluripotent stem cells and their derivatives for clinical applications. Stem Cell Reports, 9(1), 1-4.
    1. Atala, A., Bauer, S. B., Soker, S., Yoo, J. J., & Retik, A. B. (2006). Tissue-engineered autologous bladders for patients needing cystoplasty. Lancet, 367(9518), 1241-1246. https://doi.org/10.1016/S0140-6736(06)68438-9
    1. Attwood, S. W., & Edel, M. J. (2019). iPS-Cell technology and the problem of genetic instability-Can it ever be safe for clinical use? Journal of Clinical Medicine, 8(3). https://doi.org/10.3390/jcm8030288
    1. Ayala Garcia, M. A., Gonzalez Yebra, B., Lopez Flores, A. L., & Guani Guerra, E. (2012). The major histocompatibility complex in transplantation. Journal of transplantation, 2012, 842141. https://doi.org/10.1155/2012/842141

Publication types

Grants and funding

LinkOut - more resources